Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
AtriCure Inc ha un obiettivo di prezzo di consenso pari a $50.55, stabilito in base alle ultime valutazioni degli analisti di 11. Le ultime 3 valutazioni degli analisti sono state rilasciate da Needham, BTIG y UBS il julio 30, 2025, abril 30, 2025 y abril 30, 2025. Con un obiettivo di prezzo medio di $51.67 tra le Needham, BTIG y UBS, c'è un implicito 41.24% upside per AtriCure Inc da queste valutazioni degli analisti.
Firmas de analistas que realizan recomendaciones1
Needham
BTIG
UBS
JMP Securities
Citizens Capital Markets
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para AtriCure
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
07/30/2025 | 23.02% | Needham | $44 → $45 | Maintains | Buy | |||
04/30/2025 | 42.15% | BTIG | $58 → $52 | Maintains | Buy | |||
04/30/2025 | 58.56% | UBS | $60 → $58 | Maintains | Buy | |||
04/30/2025 | 64.02% | JMP Securities | $60 → $60 | Reiterates | Market Outperform → Market Outperform | |||
04/30/2025 | 20.28% | Needham | $51 → $44 | Maintains | Buy | |||
04/02/2025 | 64.02% | Citizens Capital Markets | $60 → $60 | Reiterates | Market Outperform → Market Outperform | |||
03/28/2025 | 42.15% | Canaccord Genuity | $66 → $52 | Maintains | Buy | |||
03/27/2025 | 58.56% | BTIG | $57 → $58 | Maintains | Buy | |||
03/27/2025 | 25.75% | JP Morgan | $51 → $46 | Maintains | Overweight | |||
03/27/2025 | 39.42% | Needham | $51 → $51 | Reiterates | Buy → Buy | |||
03/21/2025 | 39.42% | Needham | $51 → $51 | Reiterates | Buy → Buy | |||
02/13/2025 | 55.82% | BTIG | $53 → $57 | Maintains | Buy | |||
02/13/2025 | 23.02% | Oppenheimer | $36 → $45 | Maintains | Outperform | |||
02/13/2025 | 36.69% | Piper Sandler | $40 → $50 | Maintains | Overweight | |||
02/13/2025 | 64.02% | JMP Securities | $60 → $60 | Reiterates | Market Outperform → Market Outperform | |||
02/13/2025 | 31.22% | Stifel | $36 → $48 | Maintains | Buy | |||
02/13/2025 | 39.42% | Needham | $51 → $51 | Reiterates | Buy → Buy | |||
02/13/2025 | 80.43% | Canaccord Genuity | $61 → $66 | Maintains | Buy | |||
02/11/2025 | 39.42% | JP Morgan | $40 → $51 | Maintains | Overweight | |||
02/10/2025 | 64.02% | JMP Securities | $60 → $60 | Reiterates | Market Outperform → Market Outperform | |||
01/22/2025 | 39.42% | Needham | $40 → $51 | Maintains | Buy | |||
01/13/2025 | 9.35% | Needham | $40 → $40 | Reiterates | Buy → Buy | |||
12/17/2024 | 9.35% | JP Morgan | → $40 | Assumes | → Overweight | |||
12/09/2024 | 66.76% | Canaccord Genuity | $53 → $61 | Maintains | Buy | |||
10/30/2024 | 44.89% | Canaccord Genuity | $49 → $53 | Maintains | Buy | |||
10/30/2024 | -1.59% | Oppenheimer | $32 → $36 | Maintains | Outperform | |||
10/30/2024 | 9.35% | JP Morgan | $30 → $40 | Maintains | Overweight | |||
10/30/2024 | 9.35% | UBS | $35 → $40 | Maintains | Buy | |||
10/30/2024 | 9.35% | Needham | $34 → $40 | Maintains | Buy | |||
07/31/2024 | 44.89% | BTIG | $58 → $53 | Maintains | Buy | |||
07/31/2024 | -17.99% | JP Morgan | $34 → $30 | Maintains | Overweight | |||
07/31/2024 | -28.92% | Stifel | $30 → $26 | Maintains | Buy | |||
07/31/2024 | 9.35% | Piper Sandler | $65 → $40 | Maintains | Overweight | |||
07/31/2024 | -7.05% | Needham | $40 → $34 | Maintains | Buy | |||
07/08/2024 | 9.35% | Needham | $40 → $40 | Reiterates | Buy → Buy | |||
05/02/2024 | 33.95% | Canaccord Genuity | $57 → $49 | Maintains | Buy | |||
05/02/2024 | -7.05% | JP Morgan | $42 → $34 | Maintains | Overweight | |||
05/02/2024 | 9.35% | Needham | $46 → $40 | Maintains | Buy | |||
04/23/2024 | -12.52% | Oppenheimer | → $32 | Upgrade | Perform → Outperform | |||
04/10/2024 | 25.75% | Needham | $46 → $46 | Reiterates | Buy → Buy | |||
02/16/2024 | 58.56% | UBS | $57 → $58 | Maintains | Buy | |||
02/16/2024 | 14.82% | Stifel | $50 → $42 | Maintains | Buy | |||
02/16/2024 | 25.75% | Needham | $44 → $46 | Maintains | Buy | |||
01/22/2024 | 55.82% | UBS | $56 → $57 | Maintains | Buy | |||
01/04/2024 | 20.28% | Needham | $49 → $44 | Maintains | Buy | |||
11/29/2023 | 64.02% | JMP Securities | → $60 | Reiterates | Market Outperform → Market Outperform | |||
11/29/2023 | 33.95% | Needham | → $49 | Reiterates | Buy → Buy | |||
11/02/2023 | 36.69% | JP Morgan | $60 → $50 | Maintains | Overweight | |||
11/02/2023 | 33.95% | Needham | $68 → $49 | Maintains | Buy | |||
10/23/2023 | 64.02% | JMP Securities | → $60 | Initiates | → Market Outperform | |||
09/29/2023 | 53.09% | UBS | → $56 | Initiates | → Buy | |||
07/26/2023 | 85.89% | Needham | $60 → $68 | Maintains | Buy | |||
06/02/2023 | 64.02% | Needham | → $60 | Reiterates | Buy → Buy | |||
05/03/2023 | 64.02% | Needham | $58 → $60 | Maintains | Buy | |||
04/17/2023 | 58.56% | Needham | → $58 | Maintains | Buy | |||
02/22/2023 | 50.36% | BTIG | $65 → $55 | Maintains | Buy | |||
02/22/2023 | 31.22% | Stifel | $55 → $48 | Maintains | Buy | |||
02/22/2023 | 102.3% | Canaccord Genuity | $81 → $74 | Maintains | Buy | |||
02/22/2023 | 58.56% | Needham | → $58 | Reiterates | → Buy | |||
02/06/2023 | 121.43% | Canaccord Genuity | $67 → $81 | Maintains | Buy | |||
12/19/2022 | 58.56% | Needham | $55 → $58 | Maintains | Buy | |||
11/02/2022 | 77.69% | Canaccord Genuity | $72 → $65 | Maintains | Buy | |||
11/02/2022 | 50.36% | Needham | $65 → $55 | Maintains | Buy |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de AtriCure (ATRC)?
El último precio objetivo de AtriCure (NASDAQ:ATRC) fue comunicado por Needham el julio 30, 2025. La firma de analistas fijó un precio objetivo para $45.00 que espera ATRC a rise dentro de 12 meses (un posible 23.42% upside). 29 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre AtriCure (ATRC)?
La última calificación de analistas para AtriCure (NASDAQ:ATRC) fue proporcionada por Needham, y AtriCure mantuvo su buy calificación.
¿Cuándo se produjo la última revisión al alza de AtriCure (ATRC)?
La última revisión al alza de AtriCure Inc se produjo en abril 23, 2024, cuando Oppenheimer elevó su precio objetivo a $32. Oppenheimer anteriormente tenía a perform para AtriCure Inc.
¿Cuándo fue la última revisión a la baja de AtriCure (ATRC)?
No hay una última revisión a la baja para AtriCure.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para AtriCure (ATRC)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de AtriCure, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de AtriCure se registró el julio 30, 2025, por lo que la próxima calificación estará disponible en torno al julio 30, 2026.
¿Es correcta la calificación de los analistas sobre AtriCure (ATRC)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de AtriCure (ATRC) fue un mantuvo con un precio objetivo de $44.00 a $45.00. El precio actual al que cotiza AtriCure (ATRC) es de $36.46, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.